KIT and gastrointestinal stromal tumor: The development of molecular-targeted therapy has dramatically changed the prognosis for GIST; currently, median OS for metastatic disease is 5 years, and 26% to 35% of patients survive for 9 years.160 Overall, trials of imatinib have demonstrated a DCR of 70% to 85% for KIT-mutated GIST, with an mPFS of 20 to 24 months.84 TKIs have revolutionized the treatment of localized GIST as well.